Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?


Drug Profile


Alternative Names: AG 337; Nolatrexed dihydrochloride; Orataq; Thymitaq; ZX337

Latest Information Update: 17 Aug 2017

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Agouron Pharmaceuticals
  • Developer Agouron Pharmaceuticals; YM BioSciences USA
  • Class Quinazolines; Small molecules
  • Mechanism of Action Thymidylate synthase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Liver cancer
  • New Molecular Entity No

Highest Development Phases

  • Discontinued Colorectal cancer; Head and neck cancer; Liver cancer; Lung cancer; Pancreatic cancer; Prostate cancer

Most Recent Events

  • 09 May 2006 Eximias Pharmaceutical Corporation has been acquired by YM BioSciences
  • 04 Aug 2005 Eximias presented results showing that the ETHECC trial did not meet its primary endpoint
  • 22 Apr 2005 Eximias has completed enrolment in the ETHECC trial for liver cancer in Canada, Europe, South Africa and USA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top